ADORA2A and neoplasm: Most small‐molecule A2AR antagonists display poor water‐solubility and targeting, presenting a major challenge to their therapeutic delivery and preclinical evaluation.[24] To increase tumor accumulation of A2AR antagonists, we designed an acid‐responsive detachable PEG shell outside the PDA (PPDA).